# Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

> **NCT00315757** · PHASE2 · COMPLETED · sponsor: **Human Genome Sciences Inc.** · enrollment: 105 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Mapatumumab
- **BIOLOGICAL:** Mapatumumab
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00315757
- **Lead sponsor:** Human Genome Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2013-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00315757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00315757, "Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00315757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*